

Smallpox/Monkeypox Vaccine (JYNNEOS™) Administration, Eligibility, and Availability in Tennessee

General Vaccine Information: There are currently 2 vaccines licensed by the FDA for monkeypox: JYNNEOS (aka Imvamune or Imvanex) and ACAM2000.

JYNNEOS

- This vaccine will be supplied in a single dose vial which should be thawed before use. Once thawed, the vaccine may be kept at 2°C to 8°C (+36°F to +46°F) for 8 weeks after thawed. Do not refreeze.
- This vaccine is a two-dose series, with the second vaccine being administered 28 days after the first.

Eligibility for JYNNEOS

- Vaccination is available to Tennessee residents who meet the CDC's eligibility criteria, prioritizing those most at risk of exposure to someone with monkeypox.
- Please see CDC's eligibility criteria below:
 - Standard post-exposure prophylaxis (PEP), administration of JYNNEOS within 4 days of known exposure to monkeypox to avoid infection or between 4- and 14-days post-exposure to reduce severity of symptoms. Exposed individuals receiving vaccine will need to self-monitor for symptoms and prepare to isolate.
 - In addition to PEP, the PEP++ approach aims to reach individuals who are at high risk of exposure to monkeypox for post-exposure prophylaxis, even if they have not had documented exposure to someone with confirmed monkeypox. When coupled with self-isolation and other prevention measures, PEP++ may help slow the spread of the disease.
 - Gay, bisexual, or other men who have sex with men (MSM), and/or transgender, gender-nonconforming or gender non-binary individuals who report any of the following in the last 90 days (pre-exposure prophylaxis/PrEP)
 - Having multiple sex partners or anonymous sex
 - Being diagnosed with a sexually transmitted infection (STI) or HIV
 - Living with HIV
 - Receiving medications to prevent HIV infection (HIV PrEP)

Availability of JYNNEOS

- Contact your local health department to discuss availability of the JYNNEOS vaccine if you have a patient who may have been exposed to monkeypox.
- Please be aware that there is currently a limited supply of JYNNEOS, and vaccination is prioritized for individuals at highest risk of exposure to someone with monkeypox.
- In the future, we expect eligibility criteria to expand as allocation increases.

ACAM2000

- Please note that the ACAM2000 vaccine is available in greater quantities in the strategic national stockpile of JYNNEOS vaccine.
- ACAM2000 is administered as one percutaneous dose via multiple puncture technique with a bifurcated needle.
- Following a successful inoculation, a lesion (known as a "take") will develop at the site of the vaccination; the lesion may take up to 6 weeks or more to heal. The take can be spread to other parts of the body or even to other people.

[Type here]

- ACAM2000 should not be given to people with the following conditions: cardiac disease; eye disease treated with topical steroids; congenital or acquired immune deficiency disorders, including those taking immunosuppressive medications and people living with HIV (regardless of immune status); atopic dermatitis/eczema and persons with a history of atopic dermatitis/eczema or other acute or exfoliative skin conditions; infants less than 12 months of age; pregnancy
- At this time, TDH is not pursuing the deployment of ACAM2000 due to these factors.